CLAIM AMENDMENTS

1. (Currently Amended) A library of ~~viral~~ adenoviral vectors, wherein each member of the library comprises (i) a first heterologous DNA encoding a first gene product, wherein the first heterologous DNA is common to each member of the library of ~~viral~~ adenoviral vectors, and (ii) a second heterologous DNA encoding an second gene product, wherein the second heterologous DNA varies between the members of the library of ~~viral~~ adenoviral vectors.

2. (Cancelled)

3. (Original) The library of claim 1, wherein the first heterologous DNA and/or the second heterologous DNA is operably linked to an inducible promoter.

4. (Original) The library of claim 1, wherein the first heterologous DNA and the second heterologous DNA are under the control of separate regulatory elements.

5. (Original) The library of claim 1, wherein the first heterologous DNA and the second heterologous DNA are under the control of a bi-directional promoter.

6. (Original) The library of claim 1, wherein the first gene product is selected from the group consisting of an angiogenic factor, an anti-angiogenic factor, a transcription factor, a growth factor, a cytokine, an apoptotic agent, an anti-apoptotic agent, and a neurotrophic factor.

7.-8. (Withdrawn)

9. (Original) The library of claim 1, wherein the first gene product is a vascular endothelial growth factor (VEGF).

10.-11. (Withdrawn)

12. (Original) The library of claim 1, wherein the second gene product is fused to an activation domain, and the first gene product is fused to a DNA binding domain.

13.-53. (Cancelled)

54. (New) A library of serotype 35 adenoviral vectors, wherein each member of the library comprises (i) a first heterologous DNA encoding a first gene product, wherein the first heterologous DNA is common to each member of the library of adenoviral vectors, and (ii) a second heterologous DNA encoding an second gene product, wherein the second heterologous DNA varies between the members of the library of adenoviral vectors.